Enzymatic 2-Hydroxybutyrate Measurement for Dysglycemia Screening Beyond Conventional Fasting Measures
- 8 June 2026
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (8) , 1374-1379
Abstract
OBJECTIVE: We investigated whether fasting 2-hydroxybutyrate (2-HB), measured by a novel enzymatic assay (XpressGT), can provide incremental discrimination of dysglycemia beyond routine fasting measures. RESEARCH DESIGN AND METHODS: Associations of 2-HB with dysglycemia were assessed in the total Biomarkers of Personalized Medicine cohort and in the prespecified subcohort with fasting plasma glucose (FPG) <110 mg/dL and HbA1c 140 mg/dL during oral glucose tolerance testing). A sensitivity of 90% was achieved at 39 µmol/L, with a negative predictive value of 98.9%. Each 1-SD increase in 2-HB was independently associated with dysglycemia (odds ratio 2.23; P < 0.001). CONCLUSIONS: Enzymatic 2-HB measurement may serve as a screening biomarker to rule out postprandial dysglycemia in individuals with normal FPG and HbA1c.Keywords
All Related Versions
Funding Information
- Medizinische Universität Graz
- Austrian Science Fund (10)
- Austrian Science Fund (55776/COE14)
This publication has 17 references indexed in Scilit:
- Enzymatic detection of α-hydroxybutyrate, an important marker of insulin resistance, and comparison with LC-MS/MS detectionPractical Laboratory Medicine, 2024
- Metabolomic profiling of glucose homeostasis in African Americans: the Insulin Resistance Atherosclerosis Family Study (IRAS-FS)Metabolomics, 2023
- Profile of gut microbiota and serum metabolites associated with metabolic syndrome in a remote island most afflicted by obesity in JapanScientific Reports, 2022
- Oral glucose tolerance testing as a complement to fasting plasma glucose in screening for type 2 diabetes: population-based cross-sectional analyses of 146 000 health examinations in Västerbotten, SwedenBMJ Open, 2022
- Cohort profile: ‘Biomarkers of Personalised Medicine’ (BioPersMed): a single-centre prospective observational cohort study in Graz/Austria to evaluate novel biomarkers in cardiovascular and metabolic diseasesBMJ Open, 2022
- Hepatic NADH reductive stress underlies common variation in metabolic traitsNature, 2020
- Comparison of the Current Diagnostic Criterion of HbA1c with Fasting and 2-Hour Plasma Glucose ConcentrationJournal of Diabetes Research, 2016
- Serum α-hydroxybutyrate (α-HB) predicts elevated 1 h glucose levels and early-phase β-cell dysfunction during OGTTBMJ Open Diabetes Research & Care, 2014
- Use of HbA1c for Diagnoses of Diabetes and Prediabetes: Comparison with Diagnoses Based on Fasting and 2-Hr Glucose Values and Effects of Gender, Race, and AgeMetabolic Syndrome and Related Disorders, 2014
- Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO ConsultationDiabetic Medicine, 1998